Danaher Corporation $DHR Stock Holdings Boosted by ZWJ Investment Counsel Inc.

ZWJ Investment Counsel Inc. increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 2,345.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,731 shares of the conglomerate’s stock after acquiring an additional 26,597 shares during the period. ZWJ Investment Counsel Inc.’s holdings in Danaher were worth $6,144,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DHR. Birchbrook Inc. acquired a new position in shares of Danaher in the 3rd quarter worth approximately $140,000. William Allan Corp bought a new position in shares of Danaher during the 3rd quarter worth approximately $2,055,000. Mather Group LLC. lifted its position in shares of Danaher by 921.1% during the 3rd quarter. Mather Group LLC. now owns 125,665 shares of the conglomerate’s stock worth $27,841,000 after buying an additional 113,358 shares during the period. First Pacific Financial boosted its stake in Danaher by 5.3% in the 3rd quarter. First Pacific Financial now owns 3,465 shares of the conglomerate’s stock valued at $768,000 after buying an additional 175 shares in the last quarter. Finally, MPS Loria Financial Planners LLC boosted its stake in Danaher by 46.0% in the 3rd quarter. MPS Loria Financial Planners LLC now owns 7,656 shares of the conglomerate’s stock valued at $1,696,000 after buying an additional 2,413 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Stock Up 0.8%

Shares of DHR opened at $224.65 on Thursday. The company has a market capitalization of $157.93 billion, a P/E ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The business’s 50 day simple moving average is $212.92 and its 200-day simple moving average is $195.39.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company earned $0.77 EPS. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

Analysts Set New Price Targets

A number of brokerages have weighed in on DHR. Barclays upped their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Stifel Nicolaus cut their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Morgan Stanley lifted their price objective on Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Monday. Guggenheim boosted their target price on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.